Radcliffe Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Radcliffe Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-718,701	Closed	-$7.79M	–	465
2023 Q3	$7.79M	Sell	718,701 -46	-0%	-$493	0.97%	20
2023 Q2	$7.65M	Buy	718,747 +2,808	+0.4%	+$29.5K	0.65%	30
2023 Q1	$7.47M	Buy	715,939 +160,584	+29%	+$1.66M	0.47%	48
2022 Q4	$5.7M	Buy	555,355 +154,076	+38%	+$1.56M	0.18%	168
2022 Q3	$4.03M	Hold	401,279	–	–	0.1%	360
2022 Q2	$4.02M	Buy	401,279 +1,179	+0.3%	+$11.7K	0.09%	364
2022 Q1	$3.95M	Buy	+400,100	New	+$3.95M	0.09%	353

Radcliffe Capital Management's BIOS Position: Q4 2023 in Review

Radcliffe Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 718,701 shares — an estimated $7.79M sold.

Radcliffe Capital Management first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $7.79M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Radcliffe Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Radcliffe Capital Management sold 718,701 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $7.79M.
Radcliffe Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Radcliffe Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $7.79M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Radcliffe Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.